<?xml version="1.0" encoding="UTF-8"?>
<p id="p0560">Ivermectin 
 <bold>(39)</bold> (
 <xref rid="f0035" ref-type="fig">Fig. 7</xref>) is an FDA-approved broad-spectrum antiparasitic agent used in the treatment of tropical diseases, such as onchocerciasis, lymphatic filariasis, strongyloidiasis and lice. There is also evidence of its effectiveness in the management of myiasis, trichinosis, malaria, leishmaniasis, trypanosomiasis, Chagas disease and schistosomiasis as well as bed bugs, inflammatory skin lesions, epilepsy, neurological diseases, tuberculosis and some cancers.
 <xref rid="b1325" ref-type="bibr">
  <sup>265</sup>
 </xref> It is known that ivermectin is capable of inhibiting the bond between a virus and the nuclear transport mediated by the superfamily of importin proteins (IMP α/β1)
 <xref rid="b1330" ref-type="bibr">
  <sup>266</sup>
 </xref> or even by targeting the viral helicase,
 <xref rid="b1335" ref-type="bibr">267</xref>, 
 <xref rid="b1340" ref-type="bibr">268</xref> which inhibits viral RNA replication. There are several studies showing the antiviral activity of ivermectin against HIV-1 and dengue virus,
 <xref rid="b1330" ref-type="bibr">
  <sup>266</sup>
 </xref> influenza,
 <xref rid="b1345" ref-type="bibr">
  <sup>269</sup>
 </xref> DENV 1–4,
 <xref rid="b1350" ref-type="bibr">
  <sup>270</sup>
 </xref> yellow fever virus
 <sup>268</sup> and west Nile virus.
 <xref rid="b1355" ref-type="bibr">
  <sup>271</sup>
 </xref>
</p>
